ClinicalTrials.gg
CompletedNCT05845840Updated Jan 18, 2024

A Study of BRII-297 in Healthy Adult Subjects

A Phase 1 interventional study of BRII-297 and Placebo in Postpartum Depression, sponsored by Brii Biosciences Limited. Completed at 1 site in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-18.

Sponsored by Brii Biosciences Limited · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of BRII-297 in healthy adult subjects. The main aim of the study is to evaluate the safety and tolerability after single dose intramuscular administration of BRII-297. The study also aims at characterizing the PK profiles of BRII-297 and brexanolone after single dose intramuscular administration.

Participants will be enrolled in 6 cohorts (3 planned and 3 optional) with 6 participants per cohort [(4 active: 2 placebo) - Cohorts 1 \& 2] and 10 participants per cohort [(8 active: 2 placebo) - Cohorts 3 to 6].

Randomization for each cohort will be a two-step process. Sentinel subjects for each cohort will include 2 female subjects randomized 1:1 to BRII-297 or placebo who will be observed for at least 24 hours to ensure no significant safety events before administering study drug to the remaining non-sentinel subjects.

The estimated total duration for each subject is up to 43 days, including screening period (28 days), dosing period (1 day), and post-dose follow-up period (14 days). IM injections will be administered in the gluteal muscle.

Each participant in all cohorts will begin their inpatient stay at the clinical investigational site on Day -1 and remain as an inpatient at the site for sample collection and assessments for 15 days post dose (Day 15). Participants will be released at the end of the inpatient period.

02

Conditions studied

  • Postpartum Depression
03

In context

Depression, Postpartum

570 studies on the registry are indexed under Depression, Postpartum; 135 are open to participants now.

This study's enrollment of 41 is below the median of 103 across 455 interventional studies indexed under Depression, Postpartum.

Browse Depression, Postpartum studies →

Lead sponsor

Brii Biosciences Limited is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be 18 to 50 years inclusive, at the time of signing .
  2. Capable of giving signed informed consent as described in the protocol which includes compliance with the requirements and restrictions listed in the informed consent and in the protocol in the opinion of the investigator.
  3. Subjects who are healthy as determined by medical evaluation including medical history, physical examination, cardiac monitoring using 12-lead , and laboratory tests in the opinion of the investigator.
  4. Female or male

    a. Female subjects i. A female subject is eligible to participate if

    • of non- defined as premenarchal, or premenopausal with documented (subject's self-report) bilateral tubal ligation or occlusion, bilateral oophorectomy, bilateral salpingectomy, or hysterectomy; or
    • , documented as 12 months of spontaneous amenorrhea prior to Day 1, and in questionable cases, a blood sample at screening with simultaneous follicle stimulating hormone (FSH) consistent with postmenopausal status (refer to laboratory reference ranges for confirmatory levels); or
    • of childbearing potential, not pregnant, not lactating and agrees to use one of the following acceptable methods of until 30 days after the last dose of study drug:

      • total abstinence from sexual activities, or
      • double barrier method, or
      • an intrauterine device or system, or
      • established use of hormonal contraceptives including oral, implantable, injectable or transdermal contraceptives.

        b. Male subjects i. Male subjects with female partners of childbearing potential must comply withthe following contraception requirements from the time of study drug until90 days after the last dose of study drug administration.

    • total abstinence, or
    • vasectomy with documentation (subject's self-report) of azoospermia 90 days prior to Day 1 (without reversal surgery), or
    • barrier form of contraception (condom), and
    • female partner established user of an intrauterine device/system or hormonal contraceptives including oral, implantable, injectable or transdermal contraceptives.

    ii. Male subjects must also agree not to donate sperm until 90 days after dosing.

  5. Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1.
  6. Has venous access sufficient to allow for blood sampling.
  7. Has a (BMI) within the range of greater than or equal to 18.0 kg/m2 and less than or equal to 35 kg/m2, and, in the opinion of the investigator, the subject's body habitus would not preclude the ability to correctly inject intramuscularly at the site of injection.
  8. Has a maximum body weight of 120 kg.
  9. Agrees to abstain from strenuous exercise for 1 week before study Day -1 and during confinement.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, infectious, cardiovascular, gastrointestinal, neoplastic (except for basal or squamous cell cancer), neurological, or psychiatric disorder (as determined by the Investigator) capable of significantly altering the absorption of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of the data.
  2. Any major surgical procedure or hospitalization within 6 months prior to Day -1 or during the study, unless deemed not by the Investigator.
  3. A history of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator.
  4. History or presence of an abnormal which, in the Investigator's opinion, is clinically significant. A duration Fridericia greater than 450 ms obtained as an average from triplicate screening ECGs after at least 10 minutes rest at screening.
  5. Systolic blood pressure greater than 140 mmHg or a diastolic blood pressure of greater than 90 mmHg after approximately 10 minutes rest at screening.
  6. Calculated of less than 60 mL/min/1.73m2 by estimated glomerular filtration rate (eGFR) using standardized local clinical methodology.
  7. History of alcohol or other substance disorders within 1 year prior to screening, or recent use of drugs of abuse or a positive urine screen for drugs of abuse at screening in the opinion of the Investigator.
  8. History of depression or suicidal thoughts and/or behaviors within 1-year prior to screening in the opinion of the Investigator and assessed by S-STS at screening.
  9. Has an average weekly alcohol intake that exceeds 10 units per week within 30 days prior to screening. One unit: 1 glass of wine 5 oz or 150 mL; 12 oz or 360 mL of beer; 1.5 oz or 45 mL of distilled spirits.
  10. Are unwilling to stop alcohol consumption within 72 hours prior to Day -1 (as confirmed by alcohol breath screen test) and for the duration of the study.
  11. Use any tobacco- or nicotine-containing products including, but not limited to cigarettes, electronic cigarettes (of any kind), pipes, vapes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to screen, Day -1 (as confirmed by cotinine testing), and during the study.
  12. Positive drug testing at screening and/or at Day -1. Subjects should refrain from eating poppy seed-containing food (e.g., poppy cake) at least 3 days before admission as this can falsify the urine drug screen.
  13. History of intolerance to IM injection.
  14. Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study.
  15. Donated more than 500 mL of blood within 90 days before study drug administration.
  16. History of clinically significant chronic liver disease from any cause, presence of surface antigen, virus antibody or antibody.
  17. History of hepatic decompensation, including ascites, hepatic encephalopathy and/or esophageal or gastric varices.
  18. Positive COVID test on Day -1 (test conducted as per site standard procedures).
  19. Is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies (e.g., St. John's wort, milk thistle) or supplement supra-therapeutic doses of vitamins within 14 days (or 5 half-lives, whichever is longer) prior to Day 1 and throughout the study, except for those approved by the Investigator, Medical Monitor, and/or Brii Biosciences.
  20. Use of antiplatelet, anticoagulant, or antiepileptic medications within 30 days prior to Day 1 and throughout the study.
  21. Use of oral hypoglycemics, diuretics and uricosurics, antidepressants, opioids or centralnervous system acting drugs, such as benzodiazepines, within 14 days before Day 1 andthroughout the study.
  22. Consumption of foods or juices containing cranberries or pineapples, Seville oranges,grapefruit, pomegranate or caffeine (xanthine-containing products) within 72 hours priorto Day 1 and throughout the study, unless deemed acceptable by the Investigator.
  23. The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days or 5 half-lives of the investigational product (whichever is longer).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    BRII-297

    Participants will receive a BRII-297 by Intramuscular injection

    Drug: BRII-297

  • Placebo comparator
    Placebo

    Participants will receive placebo by Intramuscular injection

    Drug: Placebo

Interventions

  • DrugBRII-297

    Escalating doses of BRII-297 will be given in different cohorts i.e., Cohorts 1 through 6

    Also known as: Escalating doses of BRII-297

  • DrugPlacebo

    Escalating doses of placebo will be given in different cohorts i.e., Cohorts 1 through 6

    Also known as: Placebo to match

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events receiving BRII-297 compared to placebo

    To assess the safety and tolerability of a single infusion of BRII-297 as assessed by frequency of drug related adverse events, graded by severity.

    Time frame: Time Frame: Day 0 - Day 15

  2. Number of participants with abnormal clinical vital signs

    Vital signs include pulse rate, blood pressure, respiratory rate and tympanic temperature

    Time frame: Time Frame: Day 0 - Day 15

  3. Number of participants with abnormal clinically significant 12-lead electrocardiogram (ECG) readings

    Time frame: Time Frame: Day 0 - Day 15

  4. Number of participants with abnormal clinically significant clinical laboratory results

    Clinical laboratory tests include hematology, clinical chemistry, and liver function tests.

    Time frame: Time Frame: Day 0 - Day 15

  5. Number of participants with abnormal S-STS - Sheehan Suicidality Tracking Scale (self-report) results

    Each question is rated from 0 to 4, with the highest score the worse outcome.

    Time frame: Time Frame: Day 1 - Day 15

  6. Number of participants with abnormal SSS - Stanford Sleepiness Scale (self-report) results

    The SSS (self-report) is a subjective measure of sleepiness, The minimum value is 1 (active) and the maximum value is 7 (nearly asleep).

    Time frame: Time Frame: Day 1 - Day 15

  7. PK of BRII-279 and brexanolone: Maximum observed plasma drug concentration Cmax

    The Cmax PK parameter calculated based on the observed plasma drug concentration versus time curve

    Time frame: Time Frame: Day 0 - Day 15

  8. PK of BRII-279 and brexanolone: Time to maximum observed plasma drug concentration (Tmax)

    The PK parameter calculated will be Time to maximum observed plasma drug concentration (Tmax).

    Time frame: Time Frame: Day 0 - Day 15

  9. PK of BRII-279 and brexanolone: Area under the curve from time 0 to last measurable concentration (AUClast)

    The PK parameters calculated will be Area under the plasma drug concentration-time curve from time 0 to last measurable concentration (AUClast).

    Time frame: Time Frame: Day 0 - Day 15

  10. PK of BRII-279 and brexanolone: Area under the curve from time 0 to infinity (AUC0-inf)

    The PK parameters calculated will be Area under the curve from time 0 to infinity (AUC0-inf).

    Time frame: Time Frame: Day 0 - Day 15

  11. PK of BRII-279 and brexanolone: Terminal elimination half-life (T ½)

    The PK parameter of Terminal elimination half-life (T ½) is calculated based on the plasma drug concentration-time curve

    Time frame: Time Frame: Day 0 - Day 15

  12. PK of BRII-279 and brexanolone: Apparent clearance after extravascular administration (CL/F)

    Time frame: Time Frame: Day 0 - Day 15

  13. PK of BRII-279 and brexanolone: Apparent volume of distribution (Vz/F)

    Time frame: Time Frame: Day 0 - Day 15

07

Study locations

1 site
  • CMAX
    Adelaide, South Australia 5000, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Nov 2023, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
May 6, 2023
StartActual
May 15, 2023
Primary completionActual
Nov 21, 2023
CompletionActual
Jan 17, 2024
Last update
Jan 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05845840
Lead sponsor
Brii Biosciences Limited
Responsible party
Sponsor
First posted
May 6, 2023
Start date
May 15, 2023
Primary completion
Nov 21, 2023
Completion
Jan 17, 2024
Last update
Jan 18, 2024

Study contacts

Natasha Demi Martin
principal investigator · CMAX

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion